BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36495678)

  • 21. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
    Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
    PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
    Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
    Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
    Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
    Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.
    Lin L; Huang M; Shi X; Mayakonda A; Hu K; Jiang YY; Guo X; Chen L; Pang B; Doan N; Said JW; Xie J; Gery S; Cheng X; Lin Z; Li J; Berman BP; Yin D; Lin DC; Koeffler HP
    Nucleic Acids Res; 2019 Feb; 47(3):1255-1267. PubMed ID: 30496486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
    Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
    Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
    Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
    J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
    Goss KL; Gordon DJ
    Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
    Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
    J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B; Ji W; Xia H; Li J
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
    Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
    Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of EYA3 Protein in Ewing Sarcoma.
    Shah FH; Kim SJ
    Asian Pac J Cancer Prev; 2022 May; 23(5):1539-1545. PubMed ID: 35633536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
    Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
    Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenetic implications of early growth response 1 in Ewing sarcoma.
    Noh BJ; Jung WW; Kim HS; Park YK
    Pathology; 2019 Oct; 51(6):605-609. PubMed ID: 31466866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9.
    Fidaleo M; Svetoni F; Volpe E; Miñana B; Caporossi D; Paronetto MP
    Oncotarget; 2015 Oct; 6(31):31740-57. PubMed ID: 26450900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.